Skip to main content

Screening of cancer targeting TCRs with the z-Movi®

With the quick development of new single-cell analysis technologies it is now possible to identify cancer-targeting T-Cell Receptors (TCRs) in a single experiment.

A recent review published in Methods in Enzymology, presented the z-Movi® Cell Avidity Analyzer among the future platforms for the screening of cancer-targeting TCRs.

“This technology is a lab-on-a-chip based method that allows the assessment, at the single cell resolution, of thousands of cell-cell and cell-ligand interactions in parallel. By ultrasound, the system allows contactless manipulation of biological objects of different sizes in a high-throughput and controlled manner.”

Thanks to Prof. Michael Platten at Universität Heidelberg and the other contributing authors for acknowledging our instrument! We are glad to see that cell avidity gets the attention it deserves.

For more information, read the full article on Methods in Enzymology, titled “High-throughput discovery of cancer-targeting TCRs”.

Are you curious about z-Movi? Register to our upcoming webinar to see how this novel technology can be applied to your research!

Close Menu

For pricing, reach out to your application scientist or account manager

Open Email

Fill in our contact form, we will reach out to you!

Please include ‘Lakeview data analysis price inquiry’ in the Message box

Contact Us

Join our newsletter

Get exclusive news on the latest publications, product developments, events and breakthrough science.

By submitting the form you agree to LUMICKS' privacy policy. You can revoke your consent at any time.

Download our webinar recording:


Download our Cell Therapy (CAR-T, TCR, NK) applications deck